Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

**************************************************************

MEDTOX Scientific, Inc. (Nasdaq:MTOX) recently reported that it will hold a teleconference to discuss third quarter results on Wednesday, October 13, at 9:30 a.m. Central Time (10:30 a.m. Eastern). During the conference call, the Company may discuss and answer questions concerning business and financial developments and trends.

The Company’s responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously. MEDTOX is scheduled to release financial results for the quarter at approximately 6:00 a.m. Central Time on October 13.

MEDTOX Scientific, Inc., headquartered in St. Paul, Minn., is a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing devices. The company also supports customers with complete logistics, data and program management services. MEDTOX is a leader in providing esoteric laboratory testing services to hospitals and laboratories nationwide.

Medtronic, Inc. (NYSE:MDT) recently announced the U.S. launch of the VERTEX SELECT® Reconstruction System Posted Screw Module. The announcement was made at the 25th Annual Meeting of the North American Spine Society (NASS) in Orlando, Fla.

The Posted Screw Module is a supplement to the VERTEX SELECT Reconstruction System and broadens surgeons’ options for treating patients who require fixation of the vertebrae in the upper-thoracic spine. The VERTEX SELECT Reconstruction System consists of implants and general instruments that can be used to surgically treat patients with a variety of conditions that can contribute to spinal instability, including degenerative disc disease, spinal stenosis, fracture, tumors, and/or spondylolisthesis.

Medtronic’s Spine business, based in Memphis, Tennessee, is the global leader in today’s spine market and is committed to advancing the treatment of spinal conditions. Medtronic Spine collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopaedic and spinal conditions.

MELA Sciences, Inc. (NASDAQ:MELA) recently reported that the U.S. Food and Drug Administration has informed the company that it is moving the General and Plastic Surgery Devices Panel for MelaFind, which was originally scheduled for August 26, 2010, to November 2010.

MELA Sciences is a medical technology company focused on developing MelaFind, a non-invasive and objective computer vision system intended to aid in the detection of early melanoma. MELA Sciences designed MelaFind to assist in the evaluation of pigmented skin lesions, including atypical moles, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).

Reported by: Eric CRWE Newswire Middle East corresponden

Dow Jones Industrial Average DJIA dropped 133.96 points or 1.3 percent to 10,040.45. Standard & Poor’s 500 index also fell 1.5 percent to 1,051.87 and NASDAQ composite index declined 1.7 percent to close at 2,123.76 points for the day.

Total consolidated volume for the day stood at 4.5 billion shares. Losers to gainers traded with a ratio of three to one on the New York Stock Exchange

The Stock market plunged consecutively for the fourth day on the disappointing US economy data released today. As per the report of National Association of Realtors, homes sales dropped to an annual rate of 3.83 million as compared to expectations of 4.7 million which was already on the conservative side.

Diamond Management & Technology Consultants Inc. (NASDAQ:DTPI) reported the highest gain on Wall Street by surging 31.45 percent to close at $12.54 with total volume of 19.18 million for the day.

Citigroup (NYSE: C) remained the highest traded stock on New York Stock Exchange as usual and faced the correction of 1.07 percent to close at $3.71 with traded volume of 441.82 million shares.

Among major losers of the day Medtronic Inc (NYSE: MDT) reported the fall of 10.80 percent and closed at $31.21 with traded volume of 37.125 million shares. Sirius Inc remained the most traded stock at NASDAQ with a volume of 168.23 million shares and declined 3.03 percent to $0.96 in today’s trading session.

********************************************************************

The Views and Opinions Expressed by the author are his or her opinions only and do not necessarily reflect those of this Web-Site or its agents, affiliates, officers, directors, staff, or contractors. The author at the time of this article did not own any shares or receive any consideration financial or otherwise from any company or person mentioned or referred to in the article.